Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kuti

Showing results (151-160 of 596) with videos related to

Pageof 60
Sort By:
Pharmacotherapy|January 22, 2021
A guide to therapeutic drug monitoring of β-lactam antibioticsAndrew J Fratoni, David P Nicolau, Joseph L Kuti
Journal of Clinical Microbiology|September 20, 2019
Effect of Clinically Meaningful Antibiotic Concentrations on Recovery of Escherichia coli and Klebsiella pneumoniae Isolates from Anaerobic Blood Culture Bottles with and without Antibiotic Binding ResinsIris H Chen, David P Nicolau, Joseph L Kuti
Current Medical Research and Opinion|June 15, 2007
The development of new-onset type 2 diabetes associated with choosing a calcium channel blocker compared to a diuretic or beta-blockerEffie L Kuti, William L Baker, C Michael White
Clinics in Chest Medicine|August 27, 2011
Optimizing antibiotic pharmacodynamics in hospital-acquired and ventilator-acquired bacterial pneumoniaSeth T Housman, Joseph L Kuti, David P Nicolau
Critical Care Medicine|October 11, 2005
Pharmacodynamics of antimicrobials for the empirical treatment of nosocomial pneumonia: a report from the OPTAMA ProgramHeather K Sun, Joseph L Kuti, David P Nicolau
Infection Control and Hospital Epidemiology|July 9, 2009
Risk factors and outcomes associated with isolation of meropenem high-level-resistant Pseudomonas aeruginosaKathryn J Eagye, Joseph L Kuti, David P Nicolau
The Journal of Infection|October 28, 2006
Cefepime pharmacodynamics in patients with extended spectrum beta-lactamase (ESBL) and non-ESBL infectionsSu Young Lee, Joseph L Kuti, David P Nicolau
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|May 18, 2025
Quantification of sulbactam and durlobactam in saline and human plasma via ultra-performance liquid chromatography tandem mass spectrometryHanna F Roenfanz, David P Nicolau, Joseph L Kuti
Antimicrobial Agents and Chemotherapy|November 17, 2021
Erratum for Crandon et al., "Comparative Efficacies of Human Simulated Exposures of Telavancin and Vancomycin against Methicillin-Resistant Staphylococcus aureus with a Range of Vancomycin MICs in a Murine Pneumonia Model"Jared L Crandon, Joseph L Kuti, David P Nicolau
Antimicrobial Agents and Chemotherapy|April 23, 2020
Erratum for Asempa et al., "<i>In Vitro</i> Activity of Imipenem-Relebactam Alone or in Combination with Amikacin or Colistin against Pseudomonas aeruginosa"Tomefa E Asempa, David P Nicolau, Joseph L Kuti
Pageof 60

Showing results (151-160 of 596) with videos related to

Sort By:
Pageof 60
Pharmacotherapy|January 22, 2021
A guide to therapeutic drug monitoring of β-lactam antibioticsAndrew J Fratoni, David P Nicolau, Joseph L Kuti
Journal of Clinical Microbiology|September 20, 2019
Effect of Clinically Meaningful Antibiotic Concentrations on Recovery of Escherichia coli and Klebsiella pneumoniae Isolates from Anaerobic Blood Culture Bottles with and without Antibiotic Binding ResinsIris H Chen, David P Nicolau, Joseph L Kuti
Current Medical Research and Opinion|June 15, 2007
The development of new-onset type 2 diabetes associated with choosing a calcium channel blocker compared to a diuretic or beta-blockerEffie L Kuti, William L Baker, C Michael White
Clinics in Chest Medicine|August 27, 2011
Optimizing antibiotic pharmacodynamics in hospital-acquired and ventilator-acquired bacterial pneumoniaSeth T Housman, Joseph L Kuti, David P Nicolau
Critical Care Medicine|October 11, 2005
Pharmacodynamics of antimicrobials for the empirical treatment of nosocomial pneumonia: a report from the OPTAMA ProgramHeather K Sun, Joseph L Kuti, David P Nicolau
Infection Control and Hospital Epidemiology|July 9, 2009
Risk factors and outcomes associated with isolation of meropenem high-level-resistant Pseudomonas aeruginosaKathryn J Eagye, Joseph L Kuti, David P Nicolau
The Journal of Infection|October 28, 2006
Cefepime pharmacodynamics in patients with extended spectrum beta-lactamase (ESBL) and non-ESBL infectionsSu Young Lee, Joseph L Kuti, David P Nicolau
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|May 18, 2025
Quantification of sulbactam and durlobactam in saline and human plasma via ultra-performance liquid chromatography tandem mass spectrometryHanna F Roenfanz, David P Nicolau, Joseph L Kuti
Antimicrobial Agents and Chemotherapy|November 17, 2021
Erratum for Crandon et al., "Comparative Efficacies of Human Simulated Exposures of Telavancin and Vancomycin against Methicillin-Resistant Staphylococcus aureus with a Range of Vancomycin MICs in a Murine Pneumonia Model"Jared L Crandon, Joseph L Kuti, David P Nicolau
Antimicrobial Agents and Chemotherapy|April 23, 2020
Erratum for Asempa et al., "<i>In Vitro</i> Activity of Imipenem-Relebactam Alone or in Combination with Amikacin or Colistin against Pseudomonas aeruginosa"Tomefa E Asempa, David P Nicolau, Joseph L Kuti
Pageof 60